---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-093371"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2026-08-10T20:12:20+00:00"
generated_at: "2026-08-10T20:13:07.457747+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q2 revenue down 4% to $19.3M, withdraws FY2026 guidance

## Summary
- Q2 2026 revenue $19.3M, down 4% from $20.2M; gross margin 72% vs 70%.
- Net loss widened to $11.3M from $9.9M; operating loss $9.3M; cash $30.4M.
- Heather Getz appointed CEO and Director effective August 4, 2026.
- International revenue up 26%, OviTex units up 12%, LiquiFix revenue up 39% YoY.
- Full-year 2026 revenue guidance withdrawn; company cites PRS volume decline.

## SEC filing metadata
- accession: 0001104659-26-093371
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2026-08-10T20:12:20+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465926093371/0001104659-26-093371-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465926093371/tm2622768d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-093371
- JSON: https://secwatch.observer/filing/0001104659-26-093371.json
- Plain text: https://secwatch.observer/filing/0001104659-26-093371.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.